EBS vs. INVA, OPK, IRWD, LXRX, VNDA, XOMA, AGEN, CDXS, ACHV, and RIGL
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Agenus (AGEN), Codexis (CDXS), Achieve Life Sciences (ACHV), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry.
Innoviva (NASDAQ:INVA) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
Emergent BioSolutions received 117 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 66.45% of users gave Emergent BioSolutions an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of -47.68%. Emergent BioSolutions' return on equity of 28.94% beat Innoviva's return on equity.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 1.4% of Innoviva shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Innoviva and Innoviva both had 2 articles in the media. Emergent BioSolutions' average media sentiment score of 1.72 beat Innoviva's score of 0.35 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
Emergent BioSolutions has a consensus target price of $5.00, indicating a potential downside of 12.28%. Given Innoviva's higher probable upside, analysts plainly believe Emergent BioSolutions is more favorable than Innoviva.
Summary
Innoviva beats Emergent BioSolutions on 10 of the 16 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
